The Japanese medical technology group Terumo is expanding its international presence by setting up its first CDMO production site outside Japan at CHEMPARK Leverkusen. CDMO stands for "Contract Development and Manufacturing Organization" and refers to service providers that support pharmaceutical and biotech companies in the development, clinical testing, and manufacture of drugs.
Covering an area of around 13,000 square meters, Terumo will provide pharmaceutical development, filling, and packaging services and assemble autoinjectors and polymer syringes. As a first step, the company has taken over the production facility and associated quality control laboratories from the Chinese group WuXi Biologics. Around 150 highly skilled jobs are to be created.
"Terumo's new location at Chempark Leverkusen is a strong sign for Germany as a business location – and for our Chempark. Terumo's arrival increases Germany's resilience in the production of vital pharmaceutical products. It is also a positive growth signal for Germany as a business location overall. The move also shows that our diversified growth strategy for new companies is paying off," says Currenta CEO Tim Hartmann, operator of CHEMPARK.
Noritsugu Fujita, Division President, Pharmaceutical Solutions Division, Terumo, adds: "Our expanded presence in Europe and our unique CDMO capabilities will help biopharmaceutical companies bring effective treatments for chronic diseases to market more efficiently."